AllSci News
Korsana Bio emerges from stealth with USD 175m to advance THETA shuttle antibody for Alzheimer’s
Korsana Biosciences, a Waltham, Massachusetts-based biotechnology company focused on neurodegenerative diseases, issued a press release announcing it has emerged from stealth with…
Merck turns to Mayo Clinic for AI-enabled research support
Merck & Co., Inc. and Mayo Clinic announced a multi-year research and development collaboration to utilize artificial intelligence (AI) and multimodal clinical…
GSK and ViiV post data supporting long-acting HIV drug Cabenuva’s benefits over daily pills
UK-based ViiV Healthcare and GSK announced positive final data from the Phase III LATITUDE trial evaluating Cabenuva (cabotegravir and rilpivirine) in individuals…
Moderna’s flu vaccine filing accepted for FDA review following regulatory about-face
The US FDA has belatedly accepted the Biologics License Application (BLA) for Moderna’s investigational seasonal influenza vaccine, mRNA-1010, for review. The company…
Novartis reports Phase III success for remibrutinib in chronic inducible urticaria
Novartis announced positive results from its Phase III program evaluating remibrutinib in patients with chronic inducible urticaria (CIndU), with the oral Bruton’s…
Lilly’s Zepbound shows combo promise with Taltz in psoriasis
Eli Lilly and Co., announced positive results from the Phase IIIb TOGETHER-PsO study evaluating the co-administration of the IL-17A inhibitor Taltz (ixekizumab)…
Henlius pushes tetra-specific T-cell engager into the clinic for SCLC, NEC
Shanghai Henlius Biotech has registered a first-in-human Phase I clinical trial evaluating pipeline candidate HLX3901 in adults with advanced small cell lung…
CSL and Eli Lilly enter USD 100m licensing agreement for clazakizumab
Australia-based CSL Ltd, announced an exclusive licensing agreement with Indianapolis, US-based Eli Lilly and Co., for the development and commercialization of clazakizumab.…
Nektar Therapeutics partners with UCSF to explore TNFR2 agonism against multiple sclerosis
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company headquartered in San Francisco, announced an academic research collaboration with the University of California,…
J&J wins FDA nod for subcutaneous Rybrevant in NSCLC
The FDA approved a simplified once-monthly subcutaneous dosing schedule for Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) in combination with Lazcluze (lazertinib) for first-line EGFR-mutated advanced NSCLC.
BeOne Medicines launches ADAM9-targeted ADC into first-in-human study
BeOne Medicines, the global oncology company formerly known as BeiGene, has registered a clinical trial for BG-C0979, the first ADAM9-targeted antibody-drug conjugate…
Compass Pathways plots approval course for psilocybin drug after successful pivotal study
UK-based Compass Pathways announced positive topline results from its second pivotal Phase III clinical trial evaluating COMP360, a proprietary crystalline formulation of…
GSK posts real-world data for Arexvy’s long-term outcomes impact
GSK announced positive real-world evidence from a large-scale observational study evaluating Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 years…
GSK turns to JAX-NYSCF for 5-year collaboration on neurodegenerative diseases
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) and GSK plc (LSE: GSK) have entered a five-year strategic research collaboration aimed…
Wegovy picks up EC approval for higher dosage
The European Commission (EC) has granted marketing authorization to Novo Nordisk for a new, higher dosage of Wegovy (semaglutide) for the treatment…
The AllSci Brief
Systematic R&D and deal news. Daily.